Testing effectiveness (Phase 2)Ended earlyNCT02607228
What this trial is testing
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer
Gilead Sciences 31